EZElisa™小鼠补体衰变加速因子（CD55）ELISA试
剂盒-EZElisa™ Mouse Complement decay-acceleRating factor (CD55) ELISA Kit- 询价
- Biogradetech
- 美国
- A-QEK09821-96wells
- 2025年07月15日
企业认证
相关产品推荐更多 >
Donkey Cystatin 2 ELISA Kit/Donkey Cystatin 2 ELISA Kit
询价
Mouse Vascular Cell Adhesion Molecule 1 ELISA Kit/Mouse Vascular Cell Adhesion Molecule 1 ELISA Kit
询价Camel Arachidonate-15-Lipoxygenase ELISA Kit/Camel Arachidonate-15-Lipoxygenase ELISA Kit
询价
AF 594偶联试剂盒-FlyLink AF 594 Labeling Kit
询价Goat Gastrin ELISA Kit/Goat Gastrin ELISA Kit
询价
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
运输过程中保存：2-8℃
- 保质期：
1年
- 英文名：
EZElisa™ Mouse Complement decay-acceleRating factor (CD55) ELISA Kit
- 库存：
100
- 供应商：
艾美捷科技
EZElisa™小鼠补体衰变加速因子（CD55）ELISA试剂盒，EZElisa™ Mouse Complement decay-acceleRating factor (CD55) ELISA Kit，补体衰变加速因子（CD55）ELISA试剂盒, Mouse Complement decay-acceleRating factor (CD55) ELISA Kit
产品名称：EZElisa™小鼠分化簇40配体（CD40L）ELISA试剂盒-EZElisa™ Mouse Complement decay-acceleRating factor (CD55) ELISA Kit
产品货号：A-QEK09821-96wells
产品规格：96wells
Enzyme Immunoassay for the estimation of Mouse Complement decay-acceleRating factor (CD55) ELISA in serum and plasma, tissue homogenates and other biological fluids.
种属：Mouse
检测方法：比色法
检测范围：0.156-10ng/ml
该EZElisa™小鼠补体衰变加速因子（CD55）ELISA试剂盒ELISA的特点包括：即用即用的操作步骤标准化和高重复性批次之间的一致性准确性和精确性经过七个点的验证，符合金环标准质量ELISA的要求，这是Biogradetech质量的基准标志。EZElisa™ ELISA试剂盒用于评估样品中的特定生物标志物，样品可以是血清
运输过程中保存：2-8℃
点击：EZElisa™小鼠分化簇40配体（CD40L）ELISA试剂盒-EZElisa™ Mouse Complement decay-acceleRating factor (CD55) ELISA Kit更多Biogradetech产品信息价格，货期，产品说明，百度搜“艾美捷科技”进入官网网站，查看具体产品且快速下单。
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验were accurately approximated by fitting data to the same mathematical expression of exponential decay. Additionally, a high degree of correlation was found between rates of FA decay and rates of neuroanatomical development. This suggests that a common mechanism
【资源】全面归类网址：毕赤酵母表达各种来源蛋白（细菌，真菌，植物，人类等）
inhibitorS, α-MF, 180 mg/L, active541Complement receptor type 1S, 50 mg/L, α-MF, binds C3b407Cromer blood group antigen decay-accelerating factorS, α-MF[222]Cytomegalovirus ppUL44 antigenI, 0.1 mg/ml[223]Decay accelerating factor-DAF (CD55)-Echovirus
【翻译】Development trends for monoclonal antibody cancer therapeutics
, first described in 1975 (Ref 6), involved use of mouse-derived hybridomas. However, in humans, murine mAbs were commonly (although not always) ineffective as cancer therapeutics. Studies revealed that murine candidates often had short circulating half-lives
技术资料暂无技术资料 索取技术资料
